The global sevoflurane market is anticipated to rise as more procedures are performed. In Belgium, for example, 1094.3 cataract procedures, 259.6 transluminal coronary angioplasty, 232.5 cholecystectomies, and 219.5 inguinal hernia repair surgeries were carried out in 2018 per 100,000 residents, according to the European Statistical System. During the course of the forecast period, an increase in chronic diseases such as cancer, respiratory illnesses, etc. is anticipated to support the expansion of the worldwide sevoflurane market. For instance, according to GLOBOCAN 2020, there were approximately 10.0 million cancer deaths (9.9 million excluding non-melanoma skin cancer) and an estimated 19.3 million new cancer cases globally in 2020.
The Gobal Sevoflurane Market is estimated to be valued at US$ 370.2 Mn in 2022, and is expected to exhibit a CAGR of 4.4 % over the forecast period (2022-2030).
Market Leaders in the Sevoflurane Industry:
1. Abbott Laboratories
Abbott is a global healthcare leader in medical products and devices manufacturing. It serves people in more than 160 countries. Abbott was established in 1888 and is based in North Chicago, Illinois. In February, 2023 Abbott and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
2. Baxter International, Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois. The company is operational in more than 100 countries.
3. Abbvie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc.